Type 2 diabetic nephropathy
Conditions
Interventions
SGLT-2 inhibitor monotherapy group:None
Combined Medication Group:None
Finerenone Monotherapy Group:None
Sponsors
Shanghai Jing 'an District Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-85 years old, gender not limited; 2. Clearly diagnosed as type 2 diabetes and simultaneously meeting the diagnostic criteria for chronic kidney disease (CKD) : eGFR 25-90 mL/min/1.73m^2, and urine albumin/creatinine ratio (UACR) >=30 mg/g; 3. Received SGLT-2 inhibitors and/or fineridone treatment, with a continuous medication duration of >=90 days; 4. There are complete clinical examination data before and after treatment, including but not limited to eGFR, UACR, blood potassium, NT-proBNP, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), etc. It has at least one follow-up record (including efficacy or safety-related indicators), and the follow-up data is traceable.
Exclusion criteria
Exclusion criteria: 1. Severely impaired renal function: eGFR =5.5 mmol/L, and it is not controlled); 4. Special groups: Pregnant or lactating women; 5. During the observation period, drugs with clear causes of kidney damage were used: vancomycin, aminoglycosides, etc. 6. Improper medication use: Use of non-standard doses of SGLT-2 inhibitors or fineridone, or medication interruption for more than 14 days in total (medication adjustment due to adverse reactions needs to be determined by the researcher to be included); 7. Incomplete data: Ambiguous records of drug use, missing key efficacy/safety indicators (such as missing baseline and post-treatment eGFR), or untraceable follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine albumin/creatinine ratio;Estimate the glomerular filtration rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycated hemoglobin;Cardiovascular outcome-related events;Blood glucose;Urinary albumin;N-terminal pro-B-type brain natriuretic peptide;Serum potassium;Blood pressure;Safety-related adverse events; | — |
Countries
China
Contacts
Public ContactLi Yan
Jing'an District Central Hospital Of Shanghai
Outcome results
None listed